May 8, 2018 / 12:22 PM / 2 months ago

BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62

May 8 (Reuters) - CRISPR Therapeutics AG:

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

* CRISPR THERAPEUTICS AG - ON TRACK TO BEGIN CTX001 CLINICAL STUDY IN HEMOGLOBINOPATHIES IN 2018

* CRISPR THERAPEUTICS AG - ON TRACK TO FILE IND IN 2018 FOR CTX101, ALLOGENEIC CRISPR-BASED CAR-T TARGETED TOWARD CD19+ MALIGNANCIES

* CRISPR THERAPEUTICS AG - TOTAL COLLABORATION REVENUES WERE $1.4 MILLION FOR Q1 OF 2018 COMPARED TO $2.7 MILLION FOR Q1 OF 2017

* CRISPR THERAPEUTICS AG - QTRLY LOSS PER SHARE $0.62

* CRISPR THERAPEUTICS AG - HAS $341.8 MILLION IN CASH AS OF MARCH 31, 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below